GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00481458 | Esophagus | HGIN | regulation of fibroblast proliferation | 23/2587 | 80/18723 | 3.71e-04 | 5.77e-03 | 23 |
GO:00000827 | Esophagus | HGIN | G1/S transition of mitotic cell cycle | 48/2587 | 214/18723 | 3.97e-04 | 6.07e-03 | 48 |
GO:00714265 | Esophagus | HGIN | ribonucleoprotein complex export from nucleus | 22/2587 | 76/18723 | 4.44e-04 | 6.62e-03 | 22 |
GO:001604919 | Esophagus | HGIN | cell growth | 93/2587 | 482/18723 | 4.49e-04 | 6.62e-03 | 93 |
GO:00481447 | Esophagus | HGIN | fibroblast proliferation | 23/2587 | 81/18723 | 4.52e-04 | 6.62e-03 | 23 |
GO:00327866 | Esophagus | HGIN | positive regulation of DNA-templated transcription, elongation | 11/2587 | 27/18723 | 5.28e-04 | 7.56e-03 | 11 |
GO:00448437 | Esophagus | HGIN | cell cycle G1/S phase transition | 52/2587 | 241/18723 | 6.19e-04 | 8.58e-03 | 52 |
GO:19028065 | Esophagus | HGIN | regulation of cell cycle G1/S phase transition | 39/2587 | 168/18723 | 6.60e-04 | 9.03e-03 | 39 |
GO:00329685 | Esophagus | HGIN | positive regulation of transcription elongation from RNA polymerase II promoter | 7/2587 | 13/18723 | 7.61e-04 | 1.00e-02 | 7 |
GO:00064056 | Esophagus | HGIN | RNA export from nucleus | 23/2587 | 84/18723 | 7.90e-04 | 1.03e-02 | 23 |
GO:20001343 | Esophagus | HGIN | negative regulation of G1/S transition of mitotic cell cycle | 23/2587 | 84/18723 | 7.90e-04 | 1.03e-02 | 23 |
GO:00709794 | Esophagus | HGIN | protein K11-linked ubiquitination | 11/2587 | 29/18723 | 1.08e-03 | 1.32e-02 | 11 |
GO:00311243 | Esophagus | HGIN | mRNA 3'-end processing | 18/2587 | 62/18723 | 1.37e-03 | 1.61e-02 | 18 |
GO:004390320 | Esophagus | HGIN | regulation of biological process involved in symbiotic interaction | 20/2587 | 72/18723 | 1.39e-03 | 1.63e-02 | 20 |
GO:003011116 | Esophagus | HGIN | regulation of Wnt signaling pathway | 65/2587 | 328/18723 | 1.53e-03 | 1.77e-02 | 65 |
GO:00327844 | Esophagus | HGIN | regulation of DNA-templated transcription, elongation | 16/2587 | 53/18723 | 1.58e-03 | 1.79e-02 | 16 |
GO:00459305 | Esophagus | HGIN | negative regulation of mitotic cell cycle | 49/2587 | 235/18723 | 1.88e-03 | 2.01e-02 | 49 |
GO:00063764 | Esophagus | HGIN | mRNA splice site selection | 15/2587 | 49/18723 | 1.88e-03 | 2.01e-02 | 15 |
GO:001605516 | Esophagus | HGIN | Wnt signaling pathway | 83/2587 | 444/18723 | 2.27e-03 | 2.33e-02 | 83 |
GO:19019915 | Esophagus | HGIN | negative regulation of mitotic cell cycle phase transition | 39/2587 | 179/18723 | 2.31e-03 | 2.36e-02 | 39 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C7 | SNV | Missense_Mutation | | c.2353N>C | p.Glu785Gln | p.E785Q | P10643 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
C7 | SNV | Missense_Mutation | | c.320C>T | p.Ser107Phe | p.S107F | P10643 | protein_coding | tolerated(0.21) | possibly_damaging(0.77) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | rs376674018 | c.148N>T | p.Arg50Trp | p.R50W | P10643 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
C7 | SNV | Missense_Mutation | | c.1639N>C | p.Asp547His | p.D547H | P10643 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | | c.2037G>C | p.Trp679Cys | p.W679C | P10643 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | | c.944T>C | p.Val315Ala | p.V315A | P10643 | protein_coding | tolerated(0.31) | benign(0.207) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
C7 | SNV | Missense_Mutation | rs766182545 | c.2353N>A | p.Glu785Lys | p.E785K | P10643 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | novel | c.2451N>T | p.Glu817Asp | p.E817D | P10643 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
C7 | insertion | Frame_Shift_Ins | novel | c.1744_1745insGCATTAATCAGTATCTCTTGACTGAGGAAGC | p.Val582GlyfsTer14 | p.V582Gfs*14 | P10643 | protein_coding | | | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C7 | insertion | In_Frame_Ins | novel | c.2350_2350+1insCTCTGA | p.Ala784_Glu785insLeuThr | p.A784_E785insLT | P10643 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |